» Articles » PMID: 37761374

Indeterminate Thyroid Nodules: From Cytology to Molecular Testing

Overview
Specialty Radiology
Date 2023 Sep 28
PMID 37761374
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common malignancy of the endocrine system. Fine-needle aspiration (FNA) biopsy of thyroid nodules has become the gold standard procedure, in terms of cost and efficacy, for guiding clinicians towards appropriate patients' management. One challenge for cytopathologists is to accurately classify cytological specimens as benign or malignant based on cytomorphological features. In fact, with a frequency ranging from 10% to 30%, nodules are diagnosed as indeterminate. In recent years, the mutational landscape of thyroid tumors has been extensively described, and two molecular profiles have been identified: -like (, and mutations; mutations; mutation; and and fusions) and -like (including mutation and and fusions). The purpose of this review is to discuss the latest molecular findings in the context of indeterminate thyroid nodules, highlighting the role of molecular tests in patients' management.

Citing Articles

The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.

Fei M, Ding D, Ouyang X, Shen W, Zhang F, Zhang B Front Oncol. 2024; 14:1414492.

PMID: 39600648 PMC: 11588734. DOI: 10.3389/fonc.2024.1414492.


Optimizing thyroid AUS nodules malignancy prediction: a comprehensive study of logistic regression and machine learning models.

Cao Y, Yang Y, Chen Y, Luan M, Hu Y, Zhang L Front Endocrinol (Lausanne). 2024; 15:1366687.

PMID: 39568807 PMC: 11576180. DOI: 10.3389/fendo.2024.1366687.


Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.

Verrienti A, Pecce V, Grani G, Del Gatto V, Barp S, Maranghi M J Endocrinol Invest. 2024; 48(3):619-631.

PMID: 39298113 PMC: 11876262. DOI: 10.1007/s40618-024-02467-3.


Diagnosing and management of thyroid nodules and goiter - current perspectives.

Studen K, Domagala B, Gaberscek S, Zaletel K, Hubalewska-Dydejczyk A Endocrine. 2024; 87(1):39-47.

PMID: 39217209 PMC: 11739261. DOI: 10.1007/s12020-024-04015-8.


Integrated Diagnostics of Thyroid Nodules.

Giovanella L, Campenni A, Tuncel M, Petranovic Ovcaricek P Cancers (Basel). 2024; 16(2).

PMID: 38254799 PMC: 10814240. DOI: 10.3390/cancers16020311.

References
1.
Cipriani N, Johnson D, Sarne D, Angelos P, Reeves W, Antic T . The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens. Endocr Pathol. 2022; 33(4):446-456. DOI: 10.1007/s12022-022-09734-0. View

2.
Tastekin E, Canberk S, Schmitt F . Follicular Growth Pattern Disease on Thyroid Fine-needle Aspiration Biopsy. Balkan Med J. 2022; 39(4):230-238. PMC: 9326944. DOI: 10.4274/balkanmedj.galenos.2022.2022-5-17. View

3.
Kakudo K . Different Threshold of Malignancy for -like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice. Cancers (Basel). 2022; 14(3). PMC: 8834283. DOI: 10.3390/cancers14030812. View

4.
Jinih M, Foley N, Osho O, Houlihan L, Toor A, Khan J . BRAF mutation as a predictor of thyroid malignancy in indeterminate nodules: A systematic review and meta-analysis. Eur J Surg Oncol. 2016; 43(7):1219-1227. DOI: 10.1016/j.ejso.2016.11.003. View

5.
Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F . Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014; 37(6):593-9. DOI: 10.1007/s40618-014-0062-0. View